Biogen Inc

+9.52 (+2.40%)
4:06:15 PM EDT: $396.00 -10.16 (-2.50%)
Products, Regulatory

Biogen And Bio-Thera Announce Positive Results From Phase 3 Study Of Bat1806, A Proposed Biosimilar Referencing Actemra® (Tocilizumab)

Published: 06/01/2021 11:50 GMT
Biogen Inc (BIIB) - Biogen and Bio-thera Announce Positive Results From Phase 3 Study of Bat1806, a Proposed Biosimilar Referencing Actemra® (tocilizumab).
Biogen Inc - Study Met Its Primary Endpoints, Demonstrating Equivalence to Reference Medicine in Patients.
Biogen Inc - Will Make a Payment of $30 Million to Bio-thera Solutions.
Biogen Inc - Should Certain Commercial Milestones Be Achieved, Bio-thera Solutions Will Be Eligible to Receive Potential Milestone Payments.
Biogen Inc - Biogen Will Also Pay Bio-thera Solutions Tiered Royalties.